UNASSIGNED: 318 Background: Muscle invasive @entity150 (MIBC) is a chemo-sensitive disease that responds to therapy before or after curative-intent radical cystectomy (RC). Neoadjuvant chemotherapy (NAC) improves @entity1349 by 5-8% in current meta-analyses. Adjuvant chemotherapy (AC) has shown benefit but is less rigorously tested. METHODS: We retrospectively reviewed the cystectomy database at our institute from 2005-2011 and analyzed @entity1 who have received NAC or AC for MIBC. The Log rank test was used to compare survival between groups and Cox regression models were used for adjusted comparisons of survival. RESULTS: 45 @entity1 (p) (13 NAC and 32 AC) were evaluated with a mean age of 65.5 years (50-82), including 77% males and 23% females. @entity1 were most commonly offered chemotherapy because of co-morbidities and performance status. NAC was most commonly @entity136 (G)/ @entity900 (n=9) and AC was usually G/ @entity902 (n=27). Sixty-nine percent of @entity1 were downstaged and 23% had a complete pathologic response following NAC. Three p in AC group had positive margins; all of these cases were @entity5 . Pathologic staging showed 84% >= T3 and 53% node positive disease. @entity1 receiving AC had a mean interval of 64.8 days (42-129) to the start of treatment. NAC and AC @entity1 received median 4.1 (3-7) and 4.5 cycles (1-12), respectively, throughout entire course of treatment. The median @entity1349 ( @entity1349 ) was 24.5 months (m) (17.1 m-not reached) and 24-month survival rate was 47%. Progression free survival (PFS) was 12.3 m (8.5-23.5 m) for all @entity1 . There was no difference for @entity1349 or PFS based on age, gender, time after surgery to first dose of therapy, or mode of therapy (NAC or AC). When adjusted for number of cycles completed, a trend toward improved median @entity1349 (not reached vs. 22 m p= 0.092 ) and a significant PFS improvement (28.5 vs 11.5 m p=0.026) with NAC vs. AC was observed. Grade 3-4 urologic @entity137 was negligible in both groups, however the AC group had a higher percentage of grade 3-4 hematologic @entity137 . CONCLUSIONS: Despite a small sample size, results from our series favor NAC based upon efficacy and tolerability for @entity1 with locally invasive @entity150 .

A single-center experience of chemotherapy for muscle-invasive XXXX after radical cystectomy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity5 :: ('MESH:D009369', 'Disease') :: ['T4 cancers'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder cancer'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity150 :: (MESH:D001749,Disease) :: ['bladder cancer']
